Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2017. The document serves as a transaction notification regarding a specific acquisition of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a specific equity transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.4042 per share |
| Total Volume | 55.231 shares |
| Transaction Date | April 18, 2017 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing details an acquisition of 55.231 ordinary shares by Ms. C Thomas (SVP, HR). This transaction resulted from the re-investment of dividends paid on April 13, 2017, on released shares from the Company's 2009 Deferred Annual Bonus Plan. The acquisition included both co-investment shares (41.365 shares) and matching award shares (13.866 shares, nil-cost option).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of a specific insider transaction.
Investor Verification Points
- Verify the identity of the PDMR (Ms. C Thomas) and her role as SVP, HR.
- Confirm the transaction date (April 18, 2017) and the specific price per share (£16.4042).
- Note that the transaction volume is nominal (55.231 shares) and relates to a deferred bonus plan dividend reinvestment.
- Confirm the transaction was executed on the London Stock Exchange.